Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors (ESMO 2023)
Table: 1021MO Best Observed Response (BOR)1 - Days on study Cohorts -n Complete Response (CR) Partial response (PR) Stable disease (SD) Progressive disease (PD) CPI-n Cervical Cancer - 8 CPS>1% 3 pts – 163, 365, 386 2 pts – 174, 241 3 pts CPI-n Uveal Melanoma - 8 2 pts – 228, 608 2 pts – 175, 294 4 pts Dedifferentiated Liposarcoma - 10 1 pt – 512 4 pts – 162, 167, 191, 216 5 pts EC – CPI-n - 10 3 pts – 168, 2882, 394 3 pts – 120, 131, 378 4 pts GCT - 4 1 pt – 3722 3 pts Total = 40 (%) 3 pts (7.5) 7 pts (17.5) 11 pts (27.5) 19 pts (47.5) Conclusions Etig in combination with nivo is safe and well tolerated. Preliminary efficacy data of prolonged on study duration with clinical benefit in immune resistant tumors supports continued evaluation in tumor types not typically responsive to anti-PD(L)1 monotherapy.